Author: Customer Service

VANCOUVER, BC, Feb. 01, 2025 (GLOBE NEWSWIRE) — Carbon Done Right Developments Inc. (“Carbon Done Right” or the “Company”) (TSXV: KLX) (FSE: Q1C), a leading provider of high-quality carbon credits sourced exclusively from afforestation and reforestation projects developed and owned by the Company, is pleased to announce that it has been granted an extension on the closing of its non-brokered private placement that was previously announced on December 20, 2024 and amended on January 8, 2025. The final tranche of the Offering is now expected to close on or before February 17, 2025, subject to certain closing conditions including, but not limited to, the receipt of all necessary approvals including the conditional approval of the TSX Venture Exchange. This news release does not constitute an offer to sell or...

VANCOUVER, BC, Feb. 01, 2025 (GLOBE NEWSWIRE) — Carbon Done Right Developments Inc. (“Carbon Done Right” or the “Company”) (TSXV: KLX) (FSE: Q1C), a leading provider of high-quality carbon credits sourced exclusively from afforestation and reforestation projects developed and owned by the Company, is pleased to announce that it has been granted an extension on the closing of its non-brokered private placement that was previously announced on December 20, 2024 and amended on January 8, 2025. The final tranche of the Offering is now expected to close on or before February 17, 2025, subject to certain closing conditions including, but not limited to, the receipt of all necessary approvals including the conditional approval of the TSX Venture Exchange.This news release does not constitute an offer to sell...

13,863 vehicles were delivered in January 2025, increasing by 37.9% year-over-year Cumulative deliveries reached 685,427 as of January 31, 2025SHANGHAI, China, Feb. 01, 2025 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its January 2025 delivery results. The Company delivered 13,863 vehicles in January 2025, representing an increase of 37.9% year-over-year. The deliveries consisted of 7,951 vehicles from the Company’s premium smart electric vehicle brand NIO, and 5,912 vehicles from the Company’s family-oriented smart electric vehicle brand ONVO. Cumulative deliveries reached 685,427 as of January 31, 2025. About NIO Inc. NIO Inc. is a pioneer and a leading company in the global smart electric...

30,350 units delivered in January 2025, up 268% year-over-yearMonthly deliveries exceeded 30,000 units for the third consecutive monthGUANGZHOU, China, Feb. 01, 2025 (GLOBE NEWSWIRE) — XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for January 2025. In January 2025, XPENG delivered 30,350 Smart EVs, representing a 268% increase year-over-year, surpassing 30,000 units for the third consecutive month. XPENG MONA M03 has delivered over 15,000 units per month for two consecutive months. Meanwhile, XPENG P7+ reached 20,000 cumulative deliveries within just two months of launch. XNGP’s monthly active user penetration rate in urban driving reached 87% in January 2025. At the same time, XPENG rolled...

BEIJING, China, Feb. 01, 2025 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 29,927 vehicles in January 2025. As of January 31, 2025, Li Auto’s cumulative deliveries reached 1,163,799. Li L6 surpassed the 200,000 cumulative delivery milestone in January 2025. Li Auto sustained its leadership as the sales champion of Chinese automotive brand in the passenger vehicle market priced at RMB200,000 and above, with Li L6 maintaining its position as the best-selling extended-range electric vehicle model in China for seven consecutive months. In January, the Company released OTA update version 7.0, introducing the new Li AD Max V13.0, to provide users with enhanced autonomous driving experience. As of January 31, 2025,...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, Jan. 31, 2025 (GLOBE NEWSWIRE) — Eat & Beyond Global Holdings Inc. (CSE: EATS) (OTCPK: EATBF) (FSE: 988) (“Eat & Beyond” or the “Company”), an investment issuer focused on the global plant-based and alternative protein sector, is pleased to announce that the Company has entered into a securities exchange agreement dated January 31, 2025 (the “Definitive Agreement”), which sets out the terms and conditions for the acquisition by the Company of 100% of the issued and outstanding shares and 100% of the outstanding warrants in the capital of Milo Media Technologies Inc. (“Milo Media”) in exchange for securities of Eat & Beyond (the “Transaction”). Pursuant to the terms of the Definitive Agreement, the material terms...

VANCOUVER, B.C., Jan. 31, 2025 (GLOBE NEWSWIRE) — Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based energy beverage company, is pleased to announce that it has secured a US$1,000,000 loan pursuant to the terms of a loan agreement (the “Loan Agreement”) dated January 29, 2025 with Maximcash Solutions LLC (“Maximcash”). Pursuant to the terms of the Loan Agreement, Maximcash agreed to loan US$1,000,000 (the “Loan”) to the Company for a period of twelve (12) months (the “Maturity”), payable in twenty four (26) bi-weekly payments with an average monthly cost of approximately US$103,333. The Loan, which was approved by consent resolution of directors of the Company, is subject to an interest rate of 43.26% calculated annually and secured against all present and after-acquired property of its...

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it intends to offer to sell common stock and warrants in an underwritten public offering. All of the common stock and warrants are to be sold by the Company. ThinkEquity is acting as sole book-running manager for the offering. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of shares of common stock and/or warrants sold in this offering to cover over-allotments, if any.The offering is subject to market conditions and there can be no assurance as to whether or...

Conference Call Scheduled for 8:30 a.m. Eastern Time WEST PALM BEACH, Fla., Jan. 31, 2025 (GLOBE NEWSWIRE) — AMG (NYSE: AMG) will report financial and operating results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 6, 2025. A conference call will be held at 8:30 a.m. Eastern time on the same day. In addition to quarterly results, the conference call may include discussion of management’s expectations of future financial and operating results. Jay C. Horgen, President and Chief Executive Officer, Thomas M. Wojcik, Chief Operating Officer, and Dava E. Ritchea, Chief Financial Officer, will host the session. Parties interested in listening to the conference call should dial 1-877-407-8291 (U.S. calls) or 1-201-689-8345 (non-U.S. calls) shortly before the call begins. The conference call will also...

IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters’ option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Beta Bionics, were approximately $212.1 million. Beta Bionics did not receive any proceeds from any sale of shares by the selling stockholders....